![Today, we will break down Dexcom. We cover the ways in which Dexcom's continuous glucose monitors have changed Diabetes treatment, the structure of the market Dexcom operates in, and where the business may find future runway.<br /> <br /> To break down Dexcom, Zack Fuss is joined by Aneal Tenjarla, an associate portfolio manager at Sofinnova BioEquities and an investor in Dexcom. <br /> <br /> For the full show notes, transcript, and links to the best content to learn more, check out the episode page here: https://www.joincolossus.com/episodes/74713183/tenjarla-dexcom-digitizing-diabetes-management<br /> -----<br /> This episode is brought to you by Canalyst. Canalyst is the leading destination for public company data and analysis. If you enjoy our exploration of what makes a company tick on Business Breakdowns, Canalyst should be the foundation for your quantitative analysis. For more information, go to canalyst.com/breakdowns.<br /> -----<br /> Business Breakdowns is a property of Colossus, Inc. For more episodes of Business Breakdowns, visit joincolossus.com/episodes.<br /> <br /> Stay up to date on all our podcasts by signing up to Colossus Weekly, our quick dive every Sunday highlighting the top business and investing concepts from our podcasts and the best of what we read that week. Sign up here.<br /> <br /> Follow us on Twitter: @JoinColossus | @patrick_oshag | @jspujji | @zbfuss<br /> <br /> Show Notes<br /> [00:00:00] - Introduction <br /> [00:02:37] - [First question] - What is Dexcom, their core product, and the size of their market<br /> [00:04:43] - Overview of the expenses that diabetics accrue annually<br /> [00:06:36] - Why continuous glucose monitors (CGMs) are important for diabetes management<br /> [00:09:57] - Dexcom’s unit economics and their current revenue model<br /> [00:14:10] - Whether or not there is a tech and regulatory barrier to entry <br /> [00:16:18] - How a diabetic or prediabetic finds their way to a Dexcom device<br /> [00:17:41] - Their current customer base and their revenue streams<br /> [00:19:31] - What dictates if a practitioner will refer patients to Dexcom or Abbott<br /> [00:21:56] - Why the problem Dexcom aims to solve is so culturally relevant today<br /> [00:25:12] - What the next chapter for Dexcom’s business could be<br /> [00:28:51] - Sizing the opportunity and optionality in this industry<br /> [00:32:11] - Thoughts on Dexcom’s capital allocation decisions<br /> [00:34:22] - Reasons why Dexcom could potentially fail in the future<br /> [00:37:59] - Competitors arising in the wearable CGM space<br /> [00:39:49] - Overview of their management team and what a good one looks like<br /> [00:42:52] - Whether or not they plan on stepping into the pump and insulin space<br /> [00:45:20] - Other externalities that consumer-friendly CGMs could create for consumers and insurance companies<br /> [00:48:56] - Lessons for builders and investors when studying Dexcom’s story<br /> [00:53:21] - A future where CGMs could be mostly implants<br /> [00:54:18] - The value unlock consumer-friendly monitoring will provide<br /><br />#businessbreakdowns #dexcom](https://media.thebusinessprofessor.com/wp-content/plugins/youtube-feed-pro/img/placeholder.png)
Today, we will break down Dexcom. We cover the ways in which Dexcom’s continuous glucose monitors have changed Diabetes treatment, the structure of the market Dexcom operates in, and where the business may find future runway.
To break down Dexcom, Zack Fuss is joined by Aneal Tenjarla, an associate portfolio manager at Sofinnova BioEquities and an investor in Dexcom.
Show Notes
[00:00:00] – Introduction
[00:02:37] – [First question] – What is Dexcom, their core product, and the size of their market
[00:04:43] – Overview of the expenses that diabetics accrue annually
[00:06:36] – Why continuous glucose monitors (CGMs) are important for diabetes management
[00:09:57] – Dexcom’s unit economics and their current revenue model
[00:14:10] – Whether or not there is a tech and regulatory barrier to entry
[00:16:18] – How a diabetic or prediabetic finds their way to a Dexcom device
[00:17:41] – Their current customer base and their revenue streams
[00:19:31] – What dictates if a practitioner will refer patients to Dexcom or Abbott
[00:21:56] – Why the problem Dexcom aims to solve is so culturally relevant today
[00:25:12] – What the next chapter for Dexcom’s business could be
[00:28:51] – Sizing the opportunity and optionality in this industry
[00:32:11] – Thoughts on Dexcom’s capital allocation decisions
[00:34:22] – Reasons why Dexcom could potentially fail in the future
[00:37:59] – Competitors arising in the wearable CGM space
[00:39:49] – Overview of their management team and what a good one looks like
[00:42:52] – Whether or not they plan on stepping into the pump and insulin space
[00:45:20] – Other externalities that consumer-friendly CGMs could create for consumers and insurance companies
[00:48:56] – Lessons for builders and investors when studying Dexcom’s story
[00:53:21] – A future where CGMs could be mostly implants
[00:54:18] – The value unlock consumer-friendly monitoring will provide